Skip to content
The Nexus
BUSINESSAug 5 · 01:06 UTCBLOOMBERGAvalon Pernell

Goldman-Backed Biotech Attovia Raises $289 Million in US IPO

Attovia Therapeutics Inc., a biotech firm developing treatments for immune system diseases with high unmet need, raised $289 million in a US initial public offering that priced at the top of its marketed range. Goldman Sachs backed the company during its IPO.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned
Attovia Therapeutics Inc.organizationGoldman Sachsorganizationimmune system diseasestopicinitial public offeringtopic
Spot something wrong with this article?Report a problem →
Forward this
Related Signal

Adjacent reporting